Acknowledgements
Breast Cancer, Cancer
BREAST CANCER, CANCER
We thank all the patients, clinicians, trials team, support staff and the Scottish Clinical Trials Research Unit who were involved in this study. The main sponsor was the Common Services Agency. Partial funding was from AstraZeneca UK Limited. Saracatinib was provided by AstraZeneca UK. We also thank the Edinburgh Biomarkers and Companion Diagnostics Group, Cancer Research UK, NCRI Breast Cancer Study Group and IDMC.